Statistics at a Glance
At a Glance
|Year||New Cases - SEER 9||New Cases - SEER 13||Deaths - SEER 9 Incidence-Based Mortality||Percent Surviving 5 Years - SEER 9|
|Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend|
Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software.
Number of New Cases and Deaths per 100,000: The number of new cases of diffuse large B-cell lymphoma was 5.5 per 100,000 men and women per year. The number of deaths was 1.8 per 100,000 men and women per year. These rates are age-adjusted and based on 2011-2015 cases and deaths.
- Mortality statistics for diffuse large B-cell lymphoma are based on SEER Incidence-Based Mortality.
How Many People Survive 5 Years Or More after Being Diagnosed with Diffuse Large B-Cell Lymphoma?
Relative survival statistics compare the survival of patients diagnosed with cancer with the survival of people in the general population who are the same age, race, and sex and who have not been diagnosed with cancer. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.
Based on data from SEER 18 2008-2014. Gray figures represent those who have died from diffuse large B-cell lymphoma. Green figures represent those who have survived 5 years or more.
SEER 18 2008-2014
Survival by Stage
Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. The earlier diffuse large B-cell lymphoma is caught, the better chance a person has of surviving five years after being diagnosed. For diffuse large B-cell lymphoma, 19.6% are diagnosed at stage I. The 5-year survival for stage I diffuse large B-cell lymphoma is 72.4%.
|Stage||Percent of Cases||5-Year Relative Survival|
Only in Originating Layer of Cells
Confined to Primary Site
Spread to Regional Lymph Nodes
Cancer has Metastasized
SEER 18 2008-2014, All Races, Both Sexes by Ann Arbor Stage
Number of New Cases
Who Gets This Cancer?
The number of new cases of diffuse large B-cell lymphoma was 5.5 per 100,000 men and women per year based on 2011-2015 cases.
|American Indian/Alaska Native||4.3|
|American Indian/Alaska Native||3.5|
SEER 18 2011-2015, Age-Adjusted
|Age Range||Percent of New Cases|
Diffuse large B-cell lymphoma is most frequently diagnosed among people aged 65-74.
SEER 18 2011-2015, All Races, Both Sexes
Trends in Rates
Changes Over Time
Keeping track of the number of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.
Using statistical models for analysis, rates for new diffuse large B-cell lymphoma cases have been falling on average 1.0% each year over the last 10 years. Death rates have been stable over 2006-2015. 5-year survival trends are shown below.
More About This Cancer
Figure: This picture shows lymph nodes above and below the diaphragm. It also shows the lymph vessels, tonsils, thymus, and spleen.
Lymphoma is cancer that begins in cells of the lymph system. The lymph system is part of the immune system, which helps the body fight infection and disease. Because lymph tissue is found all through the body, lymphoma can begin almost anywhere.
The two main types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). These can occur in both children and adults.
There are many different types of NHL that form from different types of white blood cells (B-cells, T-cells, NK cells). Most types of NHL form from B-cells. NHL may be indolent (slow-growing) or aggressive (fast-growing). The most common types of NHL in adults are diffuse large B-cell lymphoma, which is usually aggressive, and follicular lymphoma, which is usually indolent.
Here are some resources for learning more about non-Hodgkin lymphoma.
- More about risk factors for non-Hodgkin lymphoma
- More about symptoms and diagnosis of non-Hodgkin lymphoma
- More about treatment options for non-Hodgkin lymphoma
- More about clinical trials
- More about cancer prevention
All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within:
Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.
SEER Cancer Stat Facts: Diffuse Large B-Cell Lymphoma. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/dlbcl.html
These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse the SEER Cancer Statistics Review. To see statistics for a specific state, go to the State Cancer Profiles.
The statistics presented in these stat facts are based on the most recent data available, most of which can be found in the SEER Cancer Statistics Review. In some cases, different year spans may be used. Estimates for the current year are based on past data.
Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.